January 2011 in “Nuclear Techniques” Lead levels in hair increased due to environmental exposure, while iron, copper, and zinc levels stayed stable.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
2 citations
,
November 1973 in “PubMed” Sulfur-35 can be used to track hair growth and past exposure.
January 2024 in “Academic Journal of Medicine & Health Sciences” The herbal tea blend may improve hair health and overall well-being, but more research is needed.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
3 citations
,
August 2024 in “Frontiers in Oncology” Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
50 citations
,
January 2016 in “The FEBS journal” RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
4 citations
,
January 2014 in “RSC Advances” A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.
February 2026 in “Molecular Imaging and Radionuclide Therapy” High-dose radioactive iodine therapy does not harm fertility in thyroidectomy patients.
5 citations
,
January 2004 in “Biochimie” Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
September 2025 in “Value in Health” July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
December 2023 in “Ukraïnsʹkij žurnal sučasnih problem toksikologìï/Ukraïnsʹkij Žurnal Sučasnih Problem Toksikologìï” Better diagnosis and control of thallium poisoning are needed to prevent severe outcomes.
Intramuscular injection of 131I is a safe and effective way to induce hypothyroidism in rats without harming muscle tissue.
January 2026 in “Clinical Chemistry and Laboratory Medicine (CCLM)” The procedure accurately measures 5-alpha-dihydrotestosterone in blood, useful for standard tests.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
3 citations
,
May 1963 in “Radiology” Thallium poisoning can be identified through radiological signs and treated effectively with B.A.L.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
14 citations
,
March 1987 in “Journal of Investigative Dermatology”
16 citations
,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.